Largos supervivientes y terapias dirigidas en melanoma avanzado - page 25

Respuestas = 33%

Mediana SLP = 5.5 mo

Atezolizumab: fase I monoterapia

Hamid, SMR 2014

NCT01375842

Corte datos 1 enero 2014

Producto experimental, no autorizado

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,15,16,17,18,19,20,21,22,23,24 26,27,28,29,30,31,32,33,34,35,...46